Recently, there has been a shift within the pharmaceutical industry veering its R&D away from the traditional corporate campuses and moving them to new collaborative biotech clusters. Nick Sutcliffe, life sciences patent expert and partner at Mewburn Ellis, discusses the risks and opportunities of the growing biotech cluster trend.
Biotechnology
In recent years, we have seen biotech clusters become an increasingly important part of many pharmaceutical companies’ research and development strategies. Whereas major drugmakers used to carry projects through from cradle to grave on large research campuses, we are now observing a greater openness to collaboration and outside resources.